Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/35

May 25, 2025

To The Manager, **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	**Scrip Symbol - BIOCON**

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **"Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab"**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

SIDDHARTH MITTAL
Digitally signed by SIDDHARTH MITTAL
Date: 2025.05.25 13:52:18 +05'30'

Siddharth Mittal
Managing Director & CEO
DIN: 03230757

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab

Bengaluru, Karnataka, India, May 25, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations in the United Kingdom (UK) for YESINTEK®, a biosimilar of Ustekinumab.

YESINTEK® is indicated for the treatment of adults and children from the age of 6 years and older with moderate to severe plaque psoriasis, and adults with active psoriatic arthritis or moderately to severely active Crohn's disease. Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product.

In Europe, the European Commission (EC) recently granted marketing authorisation for Ustekinumab, allowing its commercialization in all European Union (EU) member states and the European Economic Area (EEA).

– Company Spokesperson